J&J Consumer Makes 'Aggressive' Shift In Digital Sales To Drive Growth
This article was originally published in The Rose Sheet
Executive Summary
When J&J CEO Gorsky says, "We're not just sitting back, we're making aggressive moves in areas such as e-commerce – investments in that shift," his words are music to analysts' ears. J&J has OTC drug and other consumer health brands to drive growth, but it's missing the digital piece, they say.
You may also be interested in...
J&J Consumer Health On Solid Footing With Help From Personal Care Sales
Analysts say firm’s consumer health division is showing signs of a comeback, with worldwide sales up 5.3% to $3.4bn, boosted 3.7% from currency exchange on strong beauty segment sales, driven by increased online marketing, and strengthening OTC drug sales.
J&J Consumer Health On Solid Footing With Help From Personal Care Sales
Analysts say firm’s consumer health division is showing signs of a comeback, with worldwide sales up 5.3% to $3.4bn, boosted 3.7% from currency exchange on strong beauty segment sales, driven by increased online marketing, and strengthening OTC drug sales.
Digital Sales Spur J&J Beauty Growth For Strengthening Consumer Business
Strong US e-commerce sales for J&J's Neutrogena and Aveeno lines drove 7.8% sales growth for its beauty division in the first quarter. Analysts say the consumer health business is showing signs of a comeback, with worldwide sales up 5.3% on a reported basis, or 1.6% excluding currency-exchange impact.